The group wants to improve on its own Welireg in a new phase 3 trial.
ApexOnco Front Page
Recent articles
Replimune gets a second chance, while Sarclisa could go subcutaneous.
2026’s first big oncology buyout is here.
Just like other oral SERDs, filing is restricted to the ESR1-mutant population.
Darovasertib data are promised for the last week of March.
The company buys in a PI3Kα and mTOR combo.
Gilead opting against IDE397 is still good news for Ideaya.
Progression-free and overall survival data from Companion-002 are due this quarter.
